Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event
Moleculin Biotech, Inc. (Nasdaq: MBRX) announces a presentation by CEO Walter Klemp at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023, at 9:00 AM ET. The event will focus on Moleculin's innovative drug candidates designed to combat resistant tumors and viruses, including Annamycin for acute myeloid leukemia and WP1066 for brain tumors. A live video webcast will be accessible, with a replay available for 90 days.
- None.
- None.
Live video webcast on Tuesday, January 17th at 9:00 AM ET
HOUSTON, Jan. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 9:00 AM ET.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714007.html
SOURCE Moleculin Biotech, Inc.
FAQ
When will Moleculin Biotech present at the Virtual Investor 2023 Companies to Watch Event?
Who will represent Moleculin at the January 17 event?
What are the main focuses of Moleculin's drug candidates?
How can I watch the Moleculin Biotech presentation?
Where can I find more information about Moleculin Biotech?
What is MBRX?
